Results 171 to 180 of about 86,601 (293)

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

Integrated Model for Predicting Cancer Therapy-Related Cardiac Dysfunction in Non-Hodgkin Lymphoma. [PDF]

Biomedicines
Bursacovschi D, Arnaut O, Ochisor V, Mihalache G, Baltaga R, Iacomi V, Robu M, Revenco V.   +7 more
europepmc   +1 more source

Validation of prognostic scores in patients with HIV‐related diffuse large B‐cell lymphoma: The value of peripheral blood parameters—A study from the Spanish Lymphoma Group GELTAMO

British Journal of Haematology, EarlyView.
Maria Huguet, Mireia Morgades, Alfredo Rivas‐Delgado, Mariana Bastos‐Oreiro, Raúl Córdoba, Antonio Salar, Fátima de la Cruz‐Vicente, Miguel Alcoceba, Blanca Ferrer‐Lores, Ana Jiménez‐Ubieto, Antonio Gutiérrez, María Infante, Sofía Huerga, Pau Abrisqueta, David Cruz, Carlos Montalbán, Ana Muntañola, Sonia González‐de Villambrosia, Josep‐Maria Ribera, José‐Tomás Navarro   +19 more
wiley   +1 more source

Recent trends of incidence and mortality of cutaneous lymphomas in Germany

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Primary cutaneous lymphomas (PCL) are primarily composed of cutaneous T‐cell lymphomas (CTCL), followed by cutaneous B‐cell lymphomas (CBCL). This study aimed to assess the incidence and survival rates of PCL in Germany. Methods We analyzed data from the North Rhine‐Westphalia Cancer Registry (2008–2021), which covers a population of
Khodr Cheikh El Najjarine, Hiltraud Kajüter, Ina Wellmann, Andreas Stang, Chalid Assaf   +4 more
wiley   +1 more source

Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non-Hodgkin lymphoma. [PDF]

Oncol Lett
Zhang X, Li G, Liu F, Shi R, Wen J, Wu W, Dai J.   +6 more
europepmc   +1 more source

Emerging Techniques in Minimally Invasive Surgery in Hematologic Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Hematologic malignancies represent the most common cancers in children. While the mainstays of treatment are chemotherapy and potentially hematopoietic stem cell transplant, minimally invasive surgery (MIS) has a role in the diagnosis and management of complications related both to disease and therapy as well as common pediatric surgical ...
Alejandro Chara, Katlyn G. McKay, Harold N. Lovvorn III, Joseph C. Fusco   +3 more
wiley   +1 more source

Beyond the Watershed: Chronic Ischemic Colitis Masking Underlying Small Bowel Non-Hodgkin Lymphoma. [PDF]

Cureus
Khan H, Hamadah Y, Jani A, Dsouza A, Baldwin J.   +4 more
europepmc   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

Follicular non-Hodgkin lymphoma recurrence in an uncommon site: the lacrimal caruncle. [PDF]

J Surg Case Rep
Ozkul E, Mangan MS, Buttanri IB, Mazmanoglu Atilman S.   +3 more
europepmc   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source